Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan

Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan An Interventional, Community Based, Comparative Study

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01354925

Acronym

DMR

Enrollment

245

Registered

2011-05-17

Start date

2011-09-30

Completion date

2011-10-31

Last updated

2013-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Type 2, Treatment During Ramadan

Keywords

Diabetes type 2, Fasting, Ramadan, Insulin analogues

Brief summary

Fasting during the Ramadan is one of the five pillars of Islam and is a mandatory duty for all healthy adult Muslims. Fasting is considered safe in young healthy subjects but it can induce harmful effects and complications in patients with diabetes. Several studies have demonstrated that patients with type 2 diabetes are prone to hypo and hyper glycemia during fasting. When treating diabetic patients with a treatment guideline the rate of these complications can be reduced. Little data is available on patients with type 2 diabetes treated with insulin. The investigators therefore propose to assess the effect of a protocol containing detemir (levemir) and a premix of insulin aspart (NovoMix70) on glucose control in patients with type 2 diabetes during the Ramadan and to compare this regimen to the standard care patients receive during this period. The investigators assume that patients receiving the intervention will have better glucose control during the Ramadan compared to patients receiving the standard care. As approximately 45 million Muslims suffer from type 2 diabetes and most of them fast during the Ramadan the results of this intervention may be significant and may improve the care of these patients allowing Muslims to respect their religious obligations without compromising their health.

Interventions

DRUGInsulin treatment during Ramadan

Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.

DRUGStandard of care

Standard of care during Ramadan according to physicians decision

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

All of these criteria should be present. 1. Patients with a diagnosis of type 2 diabetes treated with insulin (premix preparations or basal and rapid acting insulin) with or without metformin and/or a sulfonylurea drug for at least three months 2. HbA1c in the past three months ≤ 10% 3. Being capable, and willing, to perform self blood glucose monitoring and use a patient diary as required 4. Age \> 18 years

Exclusion criteria

Any of the following: 1. Patients with a diagnosis of type 1 diabetes 2. Hypoglycemia unawareness 3. Hypersensitivity to levemir 4. Hypersensitivity to NovoMix70 5. Creatinine \> 2.5 mg/l 6. AST and or ALT \> 1.5 times the upper limit 7. Pregnancy 8. Mental incapacity, unwillingness or language barrier precluding adequate understanding of the study protocol or cooperation

Design outcomes

Primary

Measure	Time frame
Difference in mean 4-point SMBG during days 23-30 of treatment between the two groups.	days 23-30 of treatment

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026